drugset / Trial / NCT07862127
RCT of Population PK-guided ATG Dosing in Haplo-HSCT
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of a population pharmacokinetics (PK)-guided targeted ATG dosing strategy in haploidentical stem cell transplantation and to observe the GVHD-free, relapse-free survival (GRFS) in the cohort receiving this strategy.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 10 mg/kg | Intravenous |